MAXCYTE INC. - COMMON

MaxCyte to Participate in Two Upcoming Investor Conferences

06 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

04 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

06 сен 2023 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte to Participate in Baird Global Healthcare Conference

05 сен 2023 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

09 авг 2023 16:05:01 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

01 авг 2023 08:05:51 Источник Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023

13 июл 2023 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

10 июл 2023 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

06 июл 2023 08:05:05 Источник Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

01 июн 2023 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

10 май 2023 16:05:01 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

04 май 2023 08:05:53 Источник Nasdaq GlobeNewswire

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

12 апр 2023 16:05:30 Источник Nasdaq GlobeNewswire

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

27 мар 2023 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results

15 мар 2023 16:05:23 Источник Nasdaq GlobeNewswire

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

08 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance

06 мар 2023 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences

01 фев 2023 16:05:53 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

03 янв 2023 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

05 дек 2022 02:00:00 Источник Nasdaq GlobeNewswire